#	Pagina
attuale pagina	/open-h2020/projects/226239/index.html

Opendata, web and dolomites

COMBINE SIGNED

Collaboration for Prevention and Treatment of MDR Bacterial Infections

Total Cost €

EC-Contrib. €

Partnership

Views

COMBINE project word cloud

Explore the words cloud of the COMBINE project. It provides you a very rough idea of what is the project "COMBINE" about.

accelerate vaccine translational bacteria form cso discovery mdr effectiveness xdr amr antibacterial capability public mycobacterium pillar fairification clinical aggregation imi2 serious office trial predictive scientific setting resistance prevent imi learnings accelerator models community collection standards building combine network antimicrobial feed standardisation infrastructure infections antibiotic treat global storage trials tuberculous translation optimisation engine caused agents discoveries cbn optimized animal relevance sharing centre mycobacteria nd4bb threat tuberculosis communication infection preclinical efficient data translocation health stringent statistical efficacy

Project "COMBINE" data sheet

The following table provides information about the project.

Coordinator	UPPSALA UNIVERSITET Organization address address: VON KRAEMERS ALLE 4 city: UPPSALA postcode: 751 05 website: www.uu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Total cost	25˙460˙100 €
EC max contribution	8˙000˙000 € (31%)
Programme	1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
Code Call	H2020-JTI-IMI2-2018-15-two-stage
Funding Scheme	IMI2-RIA
Starting year	2019
Duration (year-month-day)	from 2019-11-01 to 2025-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UPPSALA UNIVERSITET UPPSALA UNIVERSITET Organization address address: VON KRAEMERS ALLE 4 city: UPPSALA postcode: 751 05 website: www.uu.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	coordinator	3˙063˙260.00
2	BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL Organization address address: PAUL-EHRLICH-STRASSE 51-59 city: LANGEN postcode: 63225 website: www.pei.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LANGEN)	participant	1˙466˙860.00
3	GRITSYSTEMS AS GRITSYSTEMS AS Organization address address: TREKRONERGADE 126F, 3 TV city: VALBY postcode: 2500 website: www.gritsystems.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (VALBY)	participant	800˙625.00
4	FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. Organization address address: HANSASTRASSE 27C city: MUNCHEN postcode: 80686 website: www.fraunhofer.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUNCHEN)	participant	800˙000.00
5	STATENS SERUM INSTITUT STATENS SERUM INSTITUT Organization address address: ARTILLERIVEJ 5 city: KOBENHAVN S postcode: 2300 website: www.ssi.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (KOBENHAVN S)	participant	685˙000.00
6	BIOCOM BIOCOM Organization address address: LUTZOWSTRASSE 33-36 city: BERLIN postcode: 10785 website: www.biocom.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	618˙750.00
7	ASCLEPIA OUTSOURCING SOLUTIONS BVBA ASCLEPIA OUTSOURCING SOLUTIONS BVBA Organization address address: DAMVALLEISTRAAT 49 city: DESTELBERGEN postcode: 9070 website: www.asclepia.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (DESTELBERGEN)	participant	461˙250.00
8	BEAM ALLIANCE BEAM ALLIANCE Organization address address: LE DORIANT BAT B1 C:O DA VOLTERA 172 RUE DE CHARONNE city: PARIS postcode: 75011 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS)	participant	104˙255.00
9	EVOTEC INTERNATIONAL GMBH EVOTEC INTERNATIONAL GMBH Organization address address: ESSENER BOGEN 7 city: HAMBURG postcode: 22419 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HAMBURG)	participant	0.00
10	GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. Organization address address: Great West Road 980 city: BRENTFORD postcode: TW89GS website: www.gsk.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (BRENTFORD)	participant	0.00
11	JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BEERSE)	participant	0.00

Map

Project objective

The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2 AMR Accelerator will develop new agents to treat and prevent infections caused by MDR and XDR bacteria, including Mycobacterium tuberculosis and non-tuberculous mycobacteria. The COMBINE proposal addresses Pillar A, the Capability Building Network (CBN) of the AMR Accelerator programme.

The COMBINE consortium will form a Coordination and Support Office (CSO) that will support the delivery of projects across the AMR Accelerator, as well as with efficient communication among projects of the Accelerator and within the AMR community. In addition, we will establish an IT infrastructure that will allow for the FAIRification, collection, aggregation, storage, sharing, and analysis of vaccine and antibacterial preclinical and clinical data sets. When setting up the CSO, we will build on learnings from the two IMI ND4BB projects: ENABLE (an antibacterial discovery and development engine) and TRANSLOCATION (which has built an information centre for data sharing).

COMBINE partners will work to accelerate scientific discoveries in the AMR field by optimisation and standardisation of animal infection models, and development of improved models for translation of preclinical animal efficacy data and statistical analysis of clinical data. This will set new standards for the translational and predictive relevance of preclinical data and facilitate optimized design for new clinical trials. Results will feed into study and trial design throughout the AMR Accelerator to achieve more stringent and reliable development programmes.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors